Catalyst Trusteeship Limited, acting as the Debenture Trustee for debenture holders, released the remaining pledge over 36.83 lakh equity shares of Wanbury Limited held by Expert Chemicals (India) Private Limited on July 09, 2026. This action eliminated the encumbrance on the company's shares, reducing the total pledged stake to 0.00% of the total voting capital. The disclosure was submitted to BSE Limited and the National Stock Exchange of India Limited in compliance with Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Prior to this release, the acquirer held 36,83,488 shares, representing 10.54% of the total share capital, under pledge. The release of 36,83,488 shares was executed via an off-market transaction. Following this transaction, the total number of shares encumbered with the acquirer stands at zero. The total equity share capital and total diluted share capital of Wanbury Limited remain unchanged at 34,93,93,980, comprising 3,49,39,398 shares of face value ₹10 each. The acquirer clarified that it does not belong to the promoter or promoter group of the target company. Deesha Srikkanth, Senior Vice President of Catalyst Trusteeship Limited, authorized the disclosure filed on July 13, 2026.

Shareholding Details

The following table outlines the changes in the shareholding structure due to the release of the pledge:

Wanbury Limited achieved its highest-ever operational EBITDA of ₹108 crore in FY26, marking a successful turnaround and the onset of growth momentum. The pharmaceutical company reported a total revenue of ₹650 crore for the financial year, with the API business contributing ₹574 crore and the formulations business adding ₹76 crore. This performance was underpinned by operational efficiencies, debottlenecking, and balance sheet improvements, including a moderate leverage ratio of ~2X Debt/EBITDA.

Business Performance

The API segment, which accounts for 88% of the total revenue mix, recorded an 8% year-on-year growth. This business stream focuses on developed markets including the EU, Brazil, and the US, with 80% of the top line derived from exports. The company holds significant global market share in key products such as Metformin and Sertraline. In contrast, the formulations business, which is in a rebuilding phase, saw a 12% year-on-year decline in revenue to ₹76 crore. Management attributed the revenue dip in the fourth quarter to the West Asia crisis impacting API export dispatches in March.

Operational Milestones

A key milestone for the year was the launch of a new Anaesthetic API, with commercial dispatches beginning in February 2026. The company also cleared the MFDS Korea inspection with zero observations, validating its compliance systems. Wanbury continued to strengthen its regulatory credentials, maintaining approvals from USFDA, EDQM, ANVISA, and WHO GMP across its manufacturing facilities. The cumulative installed reactor capacity stands at 500 KL, with a potential for an additional 600 KL at existing sites.

Strategic Outlook

Management stated that FY26 was a pivotal year for strengthening business fundamentals. Looking ahead, the company plans to continue its API growth journey in FY27 with recent launches and a strong pipeline of four molecules scheduled for commercialisation each year. For the formulations business, the strategy focuses on leveraging its heritage to rebuild a scalable franchise, transitioning the portfolio towards speciality and chronic segments, and achieving profitability break-even in FY26 through better scale and cost-management efforts.

Financial Snapshot